18 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28131713	75	Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.	Merck Research Laboratories
25987375	20	Discovery of a novel Kv7 channel opener as a treatment for epilepsy.	Pfizer
25286150	75	Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.	Astrazeneca
25087753	240	Prediction of Thorough QT study results using action potential simulations based on ion channel screens.	University of Oxford
24937104	30	GPR103 antagonists demonstrating anorexigenic activity in vivo: design and development of pyrrolo[2,3-c]pyridines that mimic the C-terminal Arg-Phe motif of QRFP26.	Astrazeneca
22793372	66	Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.	Vanderbilt University Medical Center
24900334	89	N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.	TBA
22607672	28	MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.	Merck Research Laboratories
11356099	20	Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress.	Abbott Laboratories
21942426	113	Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.	Merck
21493064	69	Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.	Merck
11689069	18	Synthesis and activity of novel and selective I(Ks)-channel blockers.	Aventis Pharma Deutschland
31566384	134	Development of Chemical Entities Endowed with Potent Fast-Killing Properties against	Glaxosmithkline
30869888	61	Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.	TBA
30879840	36	Potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents.	Astrazeneca
30429949	59	Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition.	Merck
28753313	45	Neuroactive Steroids. 2. 3?-Hydroxy-3?-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5?-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (?-Aminobutyric Acid)	Sage Therapeutics
29172502	96	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88	Astrazeneca